- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00513526
Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men
RATIONALE: Vaccines made from human papillomavirus may help the body build an effective immune response to kill HIV cells.
PURPOSE: This phase II trial is studying the side effects and how well human papillomavirus vaccine therapy works in treating men with HIV-1 infection.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- To assess the safety and tolerability of quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) recombinant vaccine in HIV-infected men.
- To assess the immunogenicity of the quadrivalent HPV vaccine for types 6, 11, 16 and 18 in subjects who are antibody-negative at baseline.
Secondary
- To evaluate the changes in plasma HIV-1 RNA and CD4+ count after the vaccination series.
- To describe the associations of CD4+ count, nadir CD4+ count, and age on antibody response.
- To evaluate the levels and persistence of HPV 6, 11, 16, and 18 antibody titers after the vaccination series among subjects according to serostatus at baseline.
- To evaluate the oral levels of serum IgA before and after the vaccination series.
Tertiary
- To evaluate prevalent and incident HPV infections in the anal canal.
- To evaluate cytological and histological abnormalities in the anal canal.
- To evaluate prevalent and incident HPV infections in the oral cavity.
- To compare oral and anal compartmental shedding of HPV before and after vaccination.
OUTLINE: This is a multicenter study.
Patients receive quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine intramuscularly on day 0 and weeks 8 and 24.
After completion of protocol therapy, patients are followed at 7, 12, and 18 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-1793
- UCLA Clinical AIDS Research and Education (CARE) Center
-
San Francisco, California, United States, 94143
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, United States, 80204-4507
- Denver Health Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston University Cancer Research Center
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Medical Center
-
New York, New York, United States, 10021
- New York Weill Cornell Cancer Center at Cornell University
-
New York, New York, United States, 10010
- Laser Surgery Care
-
-
Washington
-
Seattle, Washington, United States, 98101
- Benaroya Research Institute at Virginia Mason Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
DISEASE CHARACTERISTICS:
Inclusion criteria:
HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by western blot prior to study entry
- HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test
- Anal human papilloma virus DNA PCR-negative for either type 16 and/or type 18 within 90 days prior to entry
If receiving antiretroviral therapy:
- Receipt of antiretroviral therapy for at least 6 months prior to entry
- No change in antiretroviral therapy within 30 days prior to entry
- CD4 cell count > 200 cells/mm³ within 90 days prior to study entry
- HIV-1 RNA < 200 copies/mL within 90 days prior to entry
If not receiving antiretroviral therapy:
- CD4 cell count ≥ 350 cells/mm³ within 90 days prior to study entry
- No plans to start antiretroviral therapy prior to week 28
- Normal anal cytological result, or atypical squamous cell of undetermined significance or low-grade squamous intraepithelial lesions (SIL) result within 90 days prior to entry
Exclusion criteria:
- Current or history of anal or perianal carcinoma
- Anal cytological result of high-grade SIL (HSIL), atypical squamous cells suggestive of HSIL, or suggestive of invasive carcinoma at screening or a history of these results
Presence of high-grade anal intraepithelial neoplasm (HGAIN) (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3), or invasive carcinoma at pre-entry, or history of HGAIN
- Current or history of anal or peri-anal condyloma is allowed
PATIENT CHARACTERISTICS:
Inclusion criteria:
- Karnofsky performance status 70-100%
- Absolute neutrophil count > 750 cells/mm³
- Hemoglobin ≥ 9.0 g/dL
- Platelet count ≥ 100,000/mm³
- Creatinine clearance ≥ 60 mL/min
- AST and ALT ≤ 3 times ULN
- Total or conjugated (direct) bilirubin ≤ 2.5 times ULN
Exclusion criteria:
- Serious medical or psychiatric illness, active drug or alcohol use, or dependence that, in the opinion of the site Investigator, would interfere with adherence to study requirements
- Serious illness requiring systemic treatment and/or hospitalization within the past 45 days
- Allergy to yeast or any of the components of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Hemophilia
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- See Disease Characteristics
Exclusion criteria:
- Prior splenectomy
- Currently receiving anticoagulation therapy other than acetylsalicylic acid
Use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids, investigational vaccines, interleukins, interferons, growth factors, or IVIG within 45 days prior to study entry
- Routine standard of care, including hepatitis A or B, influenza, or pneumococcal and tetanus vaccines are not excluded
- Hepatitis C co-infected patients are eligible provided no concurrent initiation of treatment for hepatitis C
- Prior receipt of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine or other HPV vaccine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gardasil
Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.
|
week 0, 8, 24, 128
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detectable Human Papillomavirus (HPV) Antibody to Type 6 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 6 at Baseline
Time Frame: Week 28
|
Week 28
|
|
Detectable Human Papillomavirus (HPV) Antibody to Type 11 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 11 at Baseline
Time Frame: Week 28
|
Week 28
|
|
Detectable Human Papillomavirus (HPV) Antibody to Type 16 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 16 at Baseline
Time Frame: Week 28
|
Week 28
|
|
Detectable Human Papillomavirus (HPV) Antibody to Type 18 a Month After the Completion of HPV Vaccination Series (Week 28) Among Patients Seronegative for Type 18 at Baseline
Time Frame: Week 28
|
Week 28
|
|
Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine
Time Frame: All study visits
|
Occurrence of grade 3+ adverse events that are at least probably and definitely related to the vaccine
|
All study visits
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Longitudinal Changes in CD4+ Cell Count From Baseline
Time Frame: Week 0, 4, 12, 28
|
CD4+ cell count at week 0 was subtracted from CD4+ cell counts at each of weeks 4, 12, and 28.
|
Week 0, 4, 12, 28
|
Longitudinal Changes in Plasma HIV-1 RNA From Baseline
Time Frame: Week 0, 4, 12, 28
|
Plasma HIV-1 RNA at week 0 was subtracted from plasma HIV-1 RNA at each of weeks 4, 12, and 28.
|
Week 0, 4, 12, 28
|
Evaluate Oral Levels of Serum IgA Before and After the Vaccination Series
Time Frame: Weeks 0, 28 and 76
|
Weeks 0, 28 and 76
|
|
HPV Antibody Titers to Type 6 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status
Time Frame: weeks 0, 28, and 76
|
HPV antibody titers to type 6 at baseline and weeks 28 and 76 according to baseline seropositive status will measured in Milli-Merck units per milliliters
|
weeks 0, 28, and 76
|
HPV Antibody Titers to Type 11 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status
Time Frame: weeks 0, 28, and 76
|
HPV antibody titers to type 11 at baseline and weeks 28 and 76 according to baseline seropositive status will measured in Milli-Merck units per milliliters
|
weeks 0, 28, and 76
|
HPV Antibody Titers to Type 16 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status
Time Frame: weeks 0, 28, and 76
|
HPV antibody titers to type 16 at baseline and weeks 28 and 76 according to baseline seropositive status will measured in Milli-Merck units per milliliters
|
weeks 0, 28, and 76
|
HPV Antibody Titers to Type 18 at Baseline and Weeks 28 and 76 According to Baseline Seropositive Status
Time Frame: weeks 0, 28, and 76
|
HPV antibody titers to type 18 at baseline and weeks 28 and 76 according to baseline seropositive status will measured in Milli-Merck units per milliliters
|
weeks 0, 28, and 76
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Timothy J. Wilkin, MD, MPH, Weill Medical College of Cornell University
- Principal Investigator: Joel Palefsky, MD, University of California, San Francisco
Publications and helpful links
General Publications
- Kang M, Umbleja T, Ellsworth G, Aberg J, Wilkin T. Effects of Sex, Existing Antibodies, and HIV-1-Related and Other Baseline Factors on Antibody Responses to Quadrivalent HPV Vaccine in Persons With HIV. J Acquir Immune Defic Syndr. 2022 Apr 1;89(4):414-422. doi: 10.1097/QAI.0000000000002891.
- Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010 Oct 15;202(8):1246-53. doi: 10.1086/656320.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMC-052
- U01CA121947 (U.S. NIH Grant/Contract)
- CDR0000559149 (Other Identifier: NCI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Ondine Biomedical Inc.CompletedSurgical Site Infection | Nosocomial Infection | Healthcare Associated InfectionUnited States
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site InfectionUnited States
-
Croydon Health Services NHS TrustCompletedSurgical Site Infection | Wound Infection | Cesarean Section; Infection | Perineal InfectionUnited Kingdom
-
Cairo UniversityRecruitingPostoperative Infection | Cesarean Section Complications | Vaginal InfectionEgypt
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... and other collaboratorsRecruitingProsthetic-joint Infection | Infection Hip | Infection; Knee, JointNetherlands
-
Vastra Gotaland RegionGöteborg UniversityRecruitingProsthetic Joint Infection | Hip Prosthesis Infection | Prosthetic Infection | Knee Prosthesis InfectionSweden
-
University of ZurichCompletedProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical SiteSwitzerland
-
University of ZurichCompletedProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical SiteSwitzerland
-
Duke UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedSurgical Site Infection | Infection ControlUnited States
Clinical Trials on Gardasil
-
Laval UniversityCenters for Disease Control and PreventionCompletedHuman Papillomavirus VaccinesCanada
-
Kenya Medical Research InstituteMerck Sharp & Dohme LLC; University of WashingtonCompletedHIV-1 Infection | Human Papillomavirus
-
H. Lee Moffitt Cancer Center and Research InstituteMerck Sharp & Dohme LLCCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStem Cell Transplant | Immunogenicity | Gardasil VaccineUnited States
-
Preventive Oncology International, Inc.Merck Sharp & Dohme LLC; Peru Instituto Nacional de Enfermadades Neoplasticas...CompletedCervical Cancer | Cervical Intraepithelial Neoplasia | Human Papillomavirus | Cervical Dysplasia | Cervical NeoplasmPeru
-
Tuen Mun HospitalCompletedSystemic Lupus ErythematosusChina
-
PfizerCompletedVaccines | Meningococcal VaccinesUnited States
-
PharmaJet, Inc.National Cancer Institute (NCI); National Institutes of Health (NIH)Not yet recruiting
-
Partha BasuAll India Institute of Medical Sciences, New Delhi; Tata Memorial Centre; Deutsches... and other collaboratorsActive, not recruitingCervical Cancer | Cervical Precancerous LesionsIndia